hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-13. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
== Selected awards and honors == 1977 E. Mead Johnson Award for Pediatric Research, New York, NY. 1987 Distinguished Alumnus Award, New Jersey College of Medicine, Newark, NJ. 1994 Selected as one of "The POZ 50," individuals who have most influenced the course of HIV/AIDS. 1995 AmFAR's Outstanding Research in Pediatric AIDS Award. Presented on World's AIDS Day. 2000 American Society of Microbiology Heroes in Medicine Award 2001 Research in Action Award. Presented by Treatment Action Group. December 8, 2001. New York, NY. 2007 Wheaton College Outstanding Alumnus Award for Service to Humanity 2010/2011 Purpose Prize Fellow Encore Career for continued dedication to issues of justice and equity. 2013 Bakken Invitation Honoree.
== Medical uses == Oxymetazoline is available over-the-counter as a topical decongestant in the form of oxymetazoline hydrochloride in nasal sprays. Due to its vasoconstricting properties, oxymetazoline is also used to treat nosebleeds and eye redness due to minor irritation (marketed as Visine L.R. in the form of eye drops). In the United States, oxymetazoline 1% cream was approved by the Food and Drug Administration (FDA) in January 2017 for topical treatment of persistent facial erythema (redness) associated with rosacea in adults. In July 2020, oxymetazoline received approval by the FDA for the treatment of acquired blepharoptosis (drooping eyelid).
Treatment of electron beams is created as a result of high energy electrons in an accelerator that generates electrons accelerated to 99% the speed of light. This system uses electrical energy and can be powered on and off. The high power correlates with a higher throughput and lower unit cost, but electron beams have low dose uniformity and a penetration depth of centimeters. Therefore, electron beam treatment works for products that have low thickness.
Sources: en.wikipedia.org
Following Buchner's example; enzymes are usually named according to the reaction they carry out. Typically the suffix -ase is added to the name of the substrate (e.g., lactase is the enzyme that cleaves lactose) or the type of reaction (e.g., DNA polymerase forms DNA polymers).
=== Blood–brain barrier === Efflux by P-glycoprotein also prevents circulating loperamide from effectively crossing the blood-brain barrier, so it can generally only agonize mu-opioid receptors in the peripheral nervous system, and currently has a score of one on the anticholinergic cognitive burden scale. Concurrent administration of P-glycoprotein inhibitors such as quinidine potentially allows loperamide to cross the blood-brain barrier and produce central morphine-like effects. At high doses (>70mg), loperamide can saturate P-glycoprotein (thus overcoming the efflux) and produce euphoric effects. Loperamide taken with quinidine was found to produce respiratory depression, indicative of central opioid action. High doses of loperamide have been shown to cause a mild physical dependence during preclinical studies, specifically in mice, rats, and rhesus monkeys. Symptoms of mild opiate withdrawal were observed following abrupt discontinuation of long-term treatment of animals with loperamide.
Climate change in Brazil is causing higher temperatures and longer-lasting heatwaves, changing precipitation patterns, more intense wildfires and heightened fire risk. Brazil's hydropower, agriculture and urban water supplies will be affected. Brazil's rainforests, and the Amazon, are particularly at risk to climate change. At worst, large areas of the Amazon River basin could turn into savannah, with severe consequences for global climate and local livelihoods. Extreme weather events like droughts and flash floods are causing annual losses of around R$13 billion (US$2.6 billion), equivalent to 0.1% of the country's 2022 GDP. Climate impacts could exacerbate poverty. Brazil's greenhouse gas emissions per person are higher than the global average, and Brazil is among the top 10 highest emitting countries. Greenhouse gas emissions by Brazil are over 4% of the annual world total. In 2026 the Brazilian government has launched a National Climate Change Plan which should cut greenhouse gas emissions by 59% - 67% by 2035, and make the country carbon neutral by 2050. Brazil hosted the 2025 United Nations Climate Change Conference, in which it launched the Global carbon market coalition immediately joined by 11 countries including Brazil, China, the European Union, United Kingdom. According to some calculations, a global carbon market can speed up emission reduction seven-fold.
=== Sexuality and reproduction === Older adults are not necessarily sexually inactive nor have they lost interest in sex; although the frequency of sexual activity tends to decline with age. One survey in England of people aged 60–69 recorded 86% of men and 60% of women as sexually active. It is not possible to get pregnant from semen released in a commercial swimming pool without penetration. The sperm cells would be quickly killed by the chlorinated water and would not survive long enough to reach the vagina. An examination of the hymen is not an accurate or reliable indicator one has had penetrative sex; the tearing of the hymen may have been the result of some other event, and some are born without one. Virginity tests, such as the "two-finger" test, are unscientific. Hand size and foot size do not correlate with human penis size, but finger length ratio may. While pregnancies from sex between first cousins do carry a slightly elevated risk of birth defects, this risk is often exaggerated. The risk is 5–6% (similar to that of a woman in her early 40s giving birth), compared with a baseline risk of 3–4%. The effects of inbreeding depression, while still relatively small compared to other factors (and thus difficult to control for in a scientific experiment), become more noticeable if isolated and maintained for several generations. Having sex before a sporting event or contest is not physiologically detrimental to performance.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.